Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Venetoclax With or Without Enasidenib in Older Adults With IDH2 Mutant AML
NCT06672146Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2025
- Primary completion
- Mar 2027
- Countries
- 2
01
Overview
A Phase 2 trial of enasidenib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started May 2025; status: recruiting.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06672146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672146.